The Role of Probiotics, Prebiotics and Synbiotics in Adult Gastrointestinal Health

VIEWS - 310 (Abstract) 169 (PDF)
Jin Yu Chieng, Yan Pan

Abstract


Gastrointestinal (GI) health is important because a healthy gut can maintain our general health and protect our body from infection or illness. Apart from vitamins and minerals, probiotics, prebiotics, and synbiotics have become increasingly famous as a supplement in our daily diet. Previously, a large number of studies had been performed to study the efficacy of probiotics in the prevention or treatment of illnesses. The purpose of our review is to discuss recent data on the benefits of probiotics in human’s GI health. Promising results on the effect of probiotics in the treatment of inflammatory bowel disease, particularly ulcerative colitis and pouchitis have been obtained from studies. Other reports also showed that a few probiotics can improve symptoms in irritable bowel syndrome. Saccharomyces boulardii was shown to prevent traveler’s diarrhea but further studies are needed for firm conclusions. Lactobaccilus rhamnosus and S. boulardii are recommended in the treatment of acute infectious diarrhea. There are promising indications that probiotics could be useful in the prevention or treatment of antibiotic-associated diarrhea, and a Lactobacillus-containing combination has been shown to prevent diarrhea caused by Clostridioides difficile. Addition of probiotics to current Helicobacter pylori eradication regime can further increase the eradication rate.

Keywords


Probiotics, Prebiotics, Synbiotics, Gastrointestinal health

Full Text:

Download PDF

References


Chen LA, Sears CL, 2015, Prebiotics, Probiotics, and Synbiotics. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Saunders, Elsevier, pp. 19–25.e1.

Food and Agriculture Organization, 2007, Technical Meeting on Prebiotics: Food Quality and Standards Service (AGNS). Rome, Italy: Food and Agriculture Organization of the United Nations (FAO).

Pandey KR, Naik SR, Vakil BV, 2015, Probiotics, Prebiotics and Synbiotics-a Review. J Food Sci Technol. 52:7577–87.

Fedorak RN, Feagan BG, Hotte N, et al., 2015, The Probiotic VSL#3 has Anti-Inflammatory Effects and Could Reduce Endoscopic Recurrence after Surgery for Crohn’s Disease. Clin Gastroenterol Hepatol, 13(5):928–35.e2. DOI: 10.1016/j.cgh.2014.10.031

Acurcio LB, Sandes SH, Bastos RW, et al., 2017, Milk Fermented by Lactobacillus species from Brazilian Artisanal Cheese Protect Germ-Free-Mice Against Salmonella typhimurium Infection. Benef Microbes, 8(4):579–88. DOI: 10.3920/BM2016.0163

Zaharuddin L, Mokhtar NM, Nawawi KN, et al., 2019, A Randomized Double-Blind Placebo-Controlled Trial of Probiotics in Post-Surgical Colorectal Cancer. BMC Gastroenterol, 19:131. DOI: 10.1186/s12876-019-1047-4

Hsieh MC, Tsai WH, Jheng YP, et al., 2018, The Beneficial Effects of Lactobacillus reuteri ADR-1 or ADR-3 Consumption on Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Trial. Sci Rep, 8(1):16791. DOI: 10.1038/s41598-018-35014-1

Rather IA, Bajpai VK, Kumar S, et al., 2016, Probiotics and Atopic Dermatitis: An Overview. Front Microbiol, 7:507. DOI: 10.3389/fmicb.2016.0050

Silva NO, de Brito BB, da Silva FA, et al., 2020, Probiotics in Inflammatory Bowel Disease: Does it Work? World J Meta-Anal, 8(2):54–66. DOI: 10.13105/wjma.v8.i2.54

Schultz M, Veltkamp C, Dieleman LA, et al., 2002. Lactobacillus plantarum 299v in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10 Deficient Mice. Inflamm Bowel Dis, 8(2):71–80. DOI: 10.1097/00054725-200203000-00001

Dalmasso G, Cottrez F, Imbert V, et al., 2006, Saccharomyces boulardii Inhibits Inflammatory Bowel Disease by Trapping T Cells in Mesenteric Lymph Nodes. Gastroenterology, 131(6):1812–25. DOI: 10.1053/j.gastro.2006.10.001

Kruis W, Schütz E, Fric P, et al., 1997. Double-Blind Comparison of an Oral Escherichia coli Preparation and Mesalazine in Maintaining Remission of Ulcerative Colitis. Aliment Pharmacol Ther, 11(5):853–8. DOI: 10.1046/j.1365-2036.1997.00225.x

Kruis W, Fric P, Pokrotnieks J, et al., 2004. Maintaining Remission of Ulcerative Colitis with the Probiotic Escherichia coli Nissle 1917 is as Effective as with Standard Mesalazine. Gut, 53(11):1617–23. DOI: 10.1136/gut.2003.037747

Mora D, Filardi R, Arioli S, et al., 2019. Development of Omics-Based Protocols for the Microbiological Characterization of Multi-Strain Formulations Marketed as Probiotics: The Case of VSL#3. Microb Biotechnol, 12(6):1371–86. DOI: 10.1111/1751-7915.13476

Gionchetti P, Rizzello F, Venturi A, et al., 2000. Oral Bacteriotherapy as Maintenance Treatment in Patients with Chronic Pouchitis: A Double-Blind Placebo-Controlled Trial. Gastroenterology, 119(2):305–9. DOI: 10.1053/gast.2000.9370

Sivananthan K, Petersen AM, 2018, Review of Saccharomyces boulardii as a Treatment Option in IBD. Immunopharmacol Immunotoxicol, 40(6):465–475. DOI: 10.1080/08923973.2018.1469143

Limketkai BN, Akobeng AK, Gordon M, et al., 2020. Probiotics for Induction of Remission in Crohn’s Disease. Cochrane Database Syst Rev, 7(7):CD006634. DOI: 10.1002/14651858.CD006634.pub3

Goldenberg JZ, Yap C, Lytvyn L, et al., 2017. Probiotics for the Prevention of Clostridium Difficile-Associated Diarrhea in Adults and Children. Cochrane Database Syst Rev, 12(12):CD006095. DOI: 10.1002/14651858.CD006095.pub4

McFarland LV, Evans CT, Goldstein EJ, 2018. Strain Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne), 5:124. DOI: 10.3389/fmed.2018.00124

Guarner F, Sanders ME, Eliakim R, et al., 2017. Probiotics and Prebiotics. Milwaukee, Wisconsin: World Gastroenterology Organization. Available from: https://www.worldgastroenterology.org/guidelines/global guidelines/probiotics-and prebiotics/probiotics-and prebioticsenglish [Last accessed on 2021 Sep 09].

Agamennone V, Krul CA, Rijkers G, et al., 2018, A Practical Guide for Probiotics Applied to the Case of Antibiotic-Associated Diarrhea in The Netherlands. BMC Gastroenterol, 18(1):103. DOI:10.1186/s12876-018-0831-x

Su GL, Ko CW, Bercik P, et al., 2020, AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology, 159(2):697– 705. DOI: 10.1053/j.gastro.2020.05.059

Mark SR, Bradley AC, Nicholas JB, et al., 2017, Guidelines for the Prevention and Treatment of Travelers’ Diarrhea: A Graded Expert Panel Report. J Travel Med, 24(1):S63–S80. DOI: 10.1093/jtm/tax026

McFarland LV, Goh S, 2019, Are Probiotics and Prebiotics Effective in the Prevention of Travellers’ Diarrhea: A Systematic Review and Meta-Analysis. Travel Med Infect Dis, 27:11–9. DOI: 10.1016/j.tmaid.2018.09.007

Bae JM, 2018, Prophylactic Efficacy of Probiotics on Travelers’ Diarrhea: An Adaptive Meta-Analysis of Randomized Controlled Trials. Epidemiol Health, 40:e2018043. DOI: 10.4178/epih.e2018043

Platts-Mills JA, Babji S, Bodhidatta L, et al., 2015. Pathogen Specific Burdens of Community Diarrhoea in Developing Countries: A Multisite Birth Cohort Study (MAL-ED). Lancet Global Health, 3(9):e564–75. DOI: 10.1016/S2214-109X(15)00151-5

Andi LS, Rajal KM, John AC, et al., 2017. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis, 65(12):e45–80. DOI: 10.1093/cid/cix669

Allen SJ, Martinez EG, Gregorio GV, et al., 2010. Probiotics for Treating Acute Infectious Diarrhoea. Cochrane Database Syst Rev, 2010(11):CD003048. DOI: 10.1002/14651858

Collinson S, Deans A, Padua-Zamora A, et al., 2020. Probiotics for Treating Acute Infectious Diarrhoea. Cochrane Database Syst Rev, 12(12):CD003048. DOI: 10.1002/14651858

ACG Updates Clinical Guidelines on Prevention, 2021, Diagnosis, Treatment of C, Difficile Infection. Available from: https://www.gastroenterology.acponline.org/archives/2021/05/28/1.htm [Last accessed on 2021 Oct 06].

McDonald LC, Gerding DN, Johnson S, et al., 2018, Clinical Practice Guidelines for Clostridium difficileInfection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis, 66(7):e1–48. DOI: 10.1093/cid/cix1085

McFarland LV, Ship N, Auclair J, et al., 2018, Primary Prevention of Clostridium difficile Infections with a Specific Probiotic Combining Lactobacillus acidophilus, L. casei, and L. rhamnosus Strains: Assessing the Evidence. J Hosp Infect, 99(4):443–52. DOI: 10.1016/j.jhin.2018.04.017

Gao XW, Mubasher M, Fang CY, et al., 2010, Dose Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilusCL1285 and Lactobacillus caseiLBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients. Am J Gastroenterol, 105(7):1636–41. DOI: 10.1038/ajg.2010.11

Nicole TS, Anna M, Lyubov LT, et al., 2017, Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review with Meta Regression Analysis. Gastroenterology, 152(8):1889–900 e9. DOI: 10.1053/j.gastro.2017.02.003

Ford AC, Moayyedi P, Lacy BE, et al., 2014, American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation, Am J Gastroenterol, 109(1):S2–26. DOI: 10.1038/ajg.2014.187

Zhang Y, Li L, Guo C, et al., 2016, Effects of Probiotic Type, Dose and Treatment Duration on Irritable Bowel Syndrome Diagnosed by Rome III Criteria: A Meta-Analysis. BMC Gastroenterol, 16:62. DOI: 10.1186/s12876-016-0470-z

Yuan F, Ni H, Asche CV, et al., 2017, Efficacy of Bifidobacterium infantis 35624 in Patients with Irritable Bowel Syndrome: A Meta-Analysis. Curr Med Res Opin, 33(7):1191–7. DOI: 10.1080/03007995.2017.1292230

Enck P, Zimmermann K, Menke G, et al., 2008, A Mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for Treatment of the Irritable Bowel Syndrome-a Randomized Controlled Trial with Primary Care Physicians. Neurogastroenterol Motil, 20(10):1103–9. DOI: 10.1111/j.1365-2982.2008.01156.x

Enck P, Zimmermann K, Menke G, et al., 2009, Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo. Z Gastroenterol, 47:209–14. DOI: 10.1055/s 2008-1027702

Niedzielin K, Kordecki H, Birkenfeld B, 2001, A Controlled, Double-Blind, Randomized Study on the Efficacy of Lactobacillus plantarum 299V in Patients with Irritable Bowel Syndrome. Eur J Gastroenterol Hepatol, 13:1143–7. DOI: 10.1097/00042737-200110000-00004

Constante M, De Palma G, Lu J, et al., 2021, Saccharomyces boulardii CNCM I-745 Modulates the Microbiota-Gut Brain Axis in a Humanized Mouse Model of Irritable Bowel Syndrome. Neurogastroenterol Motil, 33(3):e13985 DOI: 10.1111/nmo.13985

Paola B, Melania S, Chiara M, et al., 2017. Saccharomyces boulardii CNCM I-745 Supplementation Reduces Gastrointestinal Dysfunction in an Animal Model of IBS. PLoS One, 12(11):e0188563. DOI: 10.1371/journal.pone.0181863

Wiese M, Eljaszewicz A, Andryszczyk M, et al., 2012. Immunomodulatory Effects of Lactobacillous plantarum and Helicobacter pylori CagA+ on the Expression of Selected Superficial Molecules on Monocyte and Lymphocyte and the Synthesis of Cytokines in Whole Blood Culture. J Physiol Pharmacol, 63(3):217–224.

Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL, 2007, Helicobacter pylori and Probiotics. J Nutr,137 Suppl 2:812–8. DOI: 10.1093/jn/137.3.812S

Kim TS, Hur JW, Yu MA, et al., 2003, Antagonism of Helicobacter pylori by Bacteriocins of Lactic acid Bacteria. J Food Prot, 66(1):3–12. DOI:10.4315/0362-028x-66.1.3

Lau CS, Ward A, Chamberlain RS, 2016, Probiotics Improve the Efficacy of Standard Triple Therapy in the Eradication of Helicobacter pylori: A Meta-Analysis. Infect Drug Resist, 9:275–89. DOI: 10.2147/IDR.S117886

McFarland LV, Malfertheiner P, Huang Y, et al., 2015. Meta Analysis of Single Strain Probiotics for the Eradication of Helicobacter pylori and Prevention of Adverse Events. World J Meta-Anal, 3(2):97–117. DOI: 10.13105/wjma.v3.i2.97

Poonyam P, Chotivitayatarakorn P, Vilaichone RK, 2019. High Effective of 14-Day High-Dose PPI Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev, 20(9):2859–64. DOI: 10.31557/APJCP.2019.20.9.2859

Dore MP, Bibbò S, Pes GM, et al., 2019. Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor. Can J Infect Dis Med Microbiol, 2019:3409820.DOI: 10.1155/2019/3409820




DOI: http://dx.doi.org/10.18063/ghl.v3i2.278

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Chieng and Pan

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Recent Articles | About Journal | For Author | Fees | About Whioce

Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.